Close Menu

Bio-Techne ExoDx Prostate Test At-Home Collection Kit

Apr 15, 2020

Bio-Techne has launched the Exosome Diagnostics ExoDx Prostate Test At-Home Collection Kit for patients who are concerned about their prostate health.

The ExoDx Prostate or EPI test is a urine-based genomic test that helps inform the prostate biopsy decision.

Due to shelter in place orders issued to reduce the spread of COVID-19, appointments have been cancelled for millions of men for important procedures such as biopsies to detect the presence of prostate cancer, the firm noted. The at-home collection kit enables physicians and their patients to employ a telehealth solution when patients share frustration, anxiety, and fear over whether they might harbor high-grade prostate cancer, Bio-Techne said.

More Like This

Sep 18, 2020

Bio-Rad Laboratories StarBright Violet 515 Dye for Flow Cytometry

Bio-Rad Laboratories has launched the StarBright Violet 515 (SBV515) dye, the first of a new range of fluorescent nanoparticles for flow cytometry. SBV515 has an excitation maximum at 401 nanometers and emission maximum of 516 nanometers, offering improved brightness to better resolve rare and low antigen density populations. It has a narrow emission profile to reduce spillover into neighboring filters and minimize excitation by other lasers, making it suitable for inclusion in multicolor panels. The dye is not susceptible to photobleaching, delivers high lot-to-lot reproducibility, and is stable at 4° C with no loss of signal, Bio-Rad said.

Sep 18, 2020

Akoya Biosciences Proxima Spatial Biology Platform

Akoya Biosciences this week launched the Proxima Spatial Biology Platform to integrate rapid image acquisition and secure data sharing in the cloud. The new software is designed to allow users to visualize and analyze whole-slide, multiplexed immunofluorescence images generated by Akoya's Phenoptics platform, and will soon be expanded to visualize and analyze ultra-high-plex images generated by Akoya's CODEX platform, enabling an integrated, flexible, and scalable solution from discovery to translational and clinical research, the company said.

Sep 18, 2020

RenalytixAI: KidneyIntelX

RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients. 

The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month. 

Sep 17, 2020

Sanford Burnham Prebys Coronascape Bioinformatics Platform

Sanford Burnham Prebys Medical Discovery Institute has introduced Coronascape, a specialized version of its Metascape bioinformatics platform designed for big-data analysis of SARS-CoV-2 and COVID-19 research. The La Jolla, California-based research institute said that Coronascape is meant to serve as a multiomics data clearinghouse for efforts to develop effective targets and therapies for the novel coronavirus. SBP developed the web-based Metascape portal in partnership with the Genomics Institute of the Novartis Research Foundation and the University of California, San Diego.

Sep 15, 2020

10x Genomics Chromium Single-Cell Multiome ATAC + Gene Expression

10x Genomics has launched its Chromium Single-Cell Multiome ATAC + Gene Expression solution.

Combining the assay for transposase-accessible chromatin using sequencing with gene expression profiling by RNA sequencing, the new product enables researchers to analyze both epigenetic programming and the transcriptome in the same cell.

Sep 15, 2020

Paradigm4 Reveal: Single Cell

Paradigm4 has introduced Reveal: Single Cell, an app to help biopharmaceutical companies manage and analyze large sets of single-cell data. Reveal: Single Cell, built on top of the bioinformatics firm's SciDB database management platform, supports multiomic analysis and association. Paradigm4 said that users can choose cells across multiple studies to evaluate tissue distribution, look for variance in response to treatment, and compare normal to diseased cells. The new app is an extension of Reveal, a translational informatics platform released in 2018.

Sep 14, 2020

Bianano Genomics Lineagen EpiPanel Dx Plus

Bionano Genomics' recent acquisition Lineagen has launched the EpiPanel Dx Plus, a laboratory-developed test for epilepsy-related conditions.

The proprietary gene panel is based on 223 genes selected from a literature review, including genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen. The test is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures and can predict the recurrence risk for other members of the family and allows for personalized treatment. It has an expected diagnostic yield of 30 percent.

Sep 10, 2020

NimaGen SARS-CoV-2 WGS Kit

NimaGen of Nijmegen, the Netherlands, has launched the EasySeq SARS-CoV-2 Whole Genome Sequencing Kit. It is based on a patented reverse complement PCR (RC-PCR) library preparation method that combines target amplification and indexing into a single closed-tube PCR step, reducing hands-on time and risk of cross contamination or sample mix up. The kit includes tiled RC-PCR primer and probe pools to cover 99 percent of the viral genome with more than 90 percent read uniformity. Also included are the RC-PCR mastermix, UDI indexes, and an AmpliClean Magnetic Bead Clean-up kit.

Sep 09, 2020

CRG COVID-19 Viral Beacon Platform

The Center for Genomic Regulation (CRG) in Barcelona has launched COVID-19 Viral Beacon, a platform that lets scientists analyze raw and consensus COVID-19 genomic data from the European Nucleotide Archive (ENA), Oxford Nanopore Technologies, Illumina, NCBI/SRA, and GISAID. Users can search for specific genetic variants and explore associated metadata.

Sep 04, 2020

Combinati Q SARS-CoV-2 Triple Assay for Absolute Q Digital PCR System

Combinati has launched the Q SARS-CoV-2 Triplex Assay for its Absolute Q digital PCR system. The multiplexed, research-use-only assay detects SARS-CoV-2 nucleic acids from extracted samples in a single reaction. The workflow includes microfluidic array partitioning plates and required reagents, has one hands-on step, and provides results in 90 minutes. The assay demonstrates sensitivity down to single viral targets, enabling researchers to detect trace amounts of virus even in a high background of human genomic DNA, according to the company.

Sep 03, 2020

Emedgene Automated CNV Classification

Emedgene has added automatic classification of copy-number variants to its genomic interpretation platform, following 2020 American College of Medical Genomics (ACMG) and Clinical Genome Resource (ClinGen) guidelines. The Israeli vendor said that the new informatics tool cuts classification time by as much as 90 percent for variants that do not require literature curation and 50 percent for those that do. 

Sep 03, 2020

Yourgene Iona Nx Noninvasive Prenatal Test

Yourgene this week launched the Iona Nx Noninvasive Prenatal Test (NIPT) after having applied CE marking in June. Iona Nx is designed to run on Illumina's NextSeq 550 Dx next-generation sequencing platform, and uses the Yourgene SP150 and Yourgene QS250 instruments to combine DNA extraction, sample preparation, and enrichment ahead of the sequencing step. The QS250 is powered by Ranger technology from Coastal Genomics, which Yourgene acquired recently acquired, and features a step that enriches fetal fraction two-fold, reducing the amount of sequencing necessary and decreasing cost. The assay has greater than 99.99 percent accuracy, according to the company, and features whole-genome analysis including for trisomy 21, 18, and 13; sex chromosomal aneuploidies; other autosomal aneuploidies; and optional fetal sex determination. It will also feature microdeletion analysis in the future, the company said.

Yourgene will initially transition existing customers to the new assay in the UK and France, followed by other European territories. 

Sep 02, 2020

Castle Biosciences DecisionDx-SCC

Castle Biosciences has launched DecisionDx-SCC, its prognostic gene expression profile test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC). DecisionDx-SCC is a qRT-PCR assay of 40 genes that uses a neural network algorithm to classify individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A, or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.

Sep 02, 2020

Promega Spectrum Compact CE System

Promega has launched the Spectrum Compact CE system, a benchtop capillary electrophoresis instrument for Sanger sequencing and DNA fragment analysis it developed in collaboration with Hitachi High-Tech. The platform, first announced in 2017, can process up to 32 samples in a single run and supports applications such as microsatellite instability analysis, mixed sample analysis, forensic STR analysis, and cell line authentication.

Sep 02, 2020

Agilent SureSelect XT HS2 RNA Reagent Kit

Agilent has launched its SureSelect XT HS2 RNA Reagent Kit. The kit offers a modular design that provides a simple and parallel approach for both RNA and DNA samples, which the firm noted will help customers streamline and combine workflows without losing time optimizing different kits for different sample types.

Agilent's kit will allow customers to accurately profile gene expression and detect RNA fusions using low-input formalin-fixed paraffin-embedded samples. The kit supports 384 unique dual sample indexes and helps customers to multiplex hundreds of samples in a single sequencing run without worrying about index hopping, the firm said. The kit also features molecular barcodes for more efficient de-duplication of sequencing reads and more accurate gene expression analysis.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.